HSP90AB1 and cancer: The bifunctional compound STA-8666 consists of an HSP90 inhibitor and a topoisomerase inhibitor (SN-38) and demonstrated antitumor effects and lower systemic toxicity in preclinical studies on different cancer models (176, 177).